awmsg logo



lacosamide (Vimpat®)


Reference No. 3343


Appraisal information

lacosamide (Vimpat®) 50 mg film-coated tablet
lacosamide (Vimpat®) 100 mg film-coated tablet
lacosamide (Vimpat®) 150 mg film-coated tablet
lacosamide (Vimpat®) 200 mg film-coated tablet


Company: UCB Pharma Ltd
BNF category: Central nervous system
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from ≥ 4 years of age to ≤ 15 years of age with epilepsy
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download